Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | nuclear receptor NHR-88 | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | Nuclear hormone receptor family member nhr-19 | 0.0366 | 0.0489 | 0.0517 |
Schistosoma mansoni | thyroid hormone receptor | 0.0366 | 0.0489 | 0.0884 |
Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.0366 | 0.0489 | 0.0884 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-49 | 0.0366 | 0.0489 | 0.0517 |
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.2149 | 0.5529 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.1955 | 0.4982 | 1 |
Loa Loa (eye worm) | steroid hormone receptor | 0.0366 | 0.0489 | 0.0517 |
Echinococcus granulosus | COUP TF:Svp nuclear hormone receptor | 0.0366 | 0.0489 | 0.0884 |
Schistosoma mansoni | nuclear hormone receptor | 0.0366 | 0.0489 | 0.0884 |
Echinococcus multilocularis | hepatocyte nuclear factor 4 alpha | 0.0366 | 0.0489 | 0.0981 |
Echinococcus multilocularis | COUP TF:Svp nuclear hormone receptor | 0.0366 | 0.0489 | 0.0981 |
Schistosoma mansoni | FTZ-F1 nuclear receptor-like protein | 0.0366 | 0.0489 | 0.0884 |
Echinococcus granulosus | ecdysone induced protein 78C | 0.0366 | 0.0489 | 0.0884 |
Echinococcus multilocularis | Nuclear hormone receptor family member nhr 41 | 0.0366 | 0.0489 | 0.0981 |
Brugia malayi | Steroid receptor seven-up type 2 | 0.0366 | 0.0489 | 0.0517 |
Schistosoma mansoni | nuclear hormone receptor nor-1/nor-2 | 0.0366 | 0.0489 | 0.0884 |
Echinococcus granulosus | Nuclear hormone receptor family member nhr 41 | 0.0366 | 0.0489 | 0.0884 |
Brugia malayi | nuclear hormone receptor | 0.3536 | 0.9453 | 1 |
Brugia malayi | Nuclear hormone receptor-like 1 | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | Nuclear hormone receptor family member nhr-31 | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-31 | 0.0366 | 0.0489 | 0.0517 |
Echinococcus granulosus | FTZ F1 alpha | 0.0366 | 0.0489 | 0.0884 |
Schistosoma mansoni | steroid hormone receptor ad4bp | 0.0366 | 0.0489 | 0.0884 |
Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.0366 | 0.0489 | 0.0884 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.0366 | 0.0489 | 0.0981 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-14 | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | hypothetical protein | 0.3364 | 0.8964 | 0.9483 |
Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.0366 | 0.0489 | 0.0981 |
Brugia malayi | Nuclear hormone receptor family member nhr-14 | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-40 | 0.0366 | 0.0489 | 0.0517 |
Schistosoma mansoni | nuclear receptor 2DBD-gamma | 0.0366 | 0.0489 | 0.0884 |
Brugia malayi | Nuclear hormone receptor family member nhr-25 | 0.0366 | 0.0489 | 0.0517 |
Schistosoma mansoni | retinoid-x-receptor (RXR) | 0.0366 | 0.0489 | 0.0884 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.2149 | 0.5529 | 1 |
Brugia malayi | Nuclear hormone receptor family member nhr-25 | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | Nuclear hormone receptor family member nhr-1 | 0.0366 | 0.0489 | 0.0517 |
Echinococcus granulosus | hepatocyte nuclear factor 4 alpha | 0.0366 | 0.0489 | 0.0884 |
Brugia malayi | Nuclear hormone receptor family member nhr-40 | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.3536 | 0.9453 | 1 |
Schistosoma mansoni | Tr4/Tr2 (homologue) | 0.0366 | 0.0489 | 0.0884 |
Brugia malayi | Nuclear hormone receptor family member nhr-19 | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | Nuclear hormone receptor family member nhr-41 | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | Nuclear hormone receptor family member nhr-3 | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-41 | 0.0366 | 0.0489 | 0.0517 |
Echinococcus multilocularis | FTZ F1 alpha | 0.0366 | 0.0489 | 0.0981 |
Brugia malayi | photoreceptor-specific nuclear receptor | 0.0366 | 0.0489 | 0.0517 |
Schistosoma mansoni | photoreceptor-specific nuclear receptor related | 0.0366 | 0.0489 | 0.0884 |
Echinococcus multilocularis | ecdysone induced protein 78C | 0.0366 | 0.0489 | 0.0981 |
Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | 0.0366 | 0.0489 | 0.0517 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-1 | 0.0366 | 0.0489 | 0.0517 |
Echinococcus granulosus | FTZ F1 nuclear receptor protein | 0.0366 | 0.0489 | 0.0884 |
Schistosoma mansoni | coup transcription factor | 0.0366 | 0.0489 | 0.0884 |
Brugia malayi | ecdysteroid receptor | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | nuclear hormone receptor | 0.0366 | 0.0489 | 0.0517 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0366 | 0.0489 | 0.0981 |
Brugia malayi | Nuclear hormone receptor family member nhr-49 | 0.0366 | 0.0489 | 0.0517 |
Schistosoma mansoni | RAR-like nuclear receptor | 0.0366 | 0.0489 | 0.0884 |
Loa Loa (eye worm) | nuclear Hormone Receptor family member | 0.0366 | 0.0489 | 0.0517 |
Brugia malayi | steroid hormone receptor | 0.0366 | 0.0489 | 0.0517 |
Echinococcus multilocularis | FTZ F1 nuclear receptor protein | 0.0366 | 0.0489 | 0.0981 |
Schistosoma mansoni | thyroid hormone receptor | 0.0366 | 0.0489 | 0.0884 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ID50 (functional) | = 0.03 uM | Ability to reduce the cell count to 50% in L1210 culture cells | ChEMBL. | 3339609 |
ID50 (functional) | = 0.03 uM | Ability to reduce the cell count to 50% in L1210 culture cells | ChEMBL. | 3339609 |
K aff (binding) | = 240000 M-1 | Apparent DNA affinity constant | ChEMBL. | 3339609 |
Median survival day (functional) | = 11.8 | Median survival day in L1210 leukemia mice model when a dose of 20 mg/kg administered intravenously | ChEMBL. | 3339609 |
Median survival day (functional) | = 13.3 | Median survival day in L1210 leukemia mice model when a dose of 40 mg/kg administered intravenously | ChEMBL. | 3339609 |
Median survival day (functional) | = 15.87 | Median survival day in P388 leukemia model when a dose of 10 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median survival day (functional) | = 17.75 | Median survival day in P388 leukemia model when a dose of 20 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median survival day (functional) | = 19 | Median survival day in P388 leukemia model when a dose of 50 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
Median survival day (functional) | = 19.3 | Median survival day of B16 melanoma infected mice when a dose of 10 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median survival day (functional) | = 20.75 | Median survival day in P388 cell line when a dose of 40 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Median survival day (functional) | = 23 | Median survival day in P388 leukemia model when a dose of 80 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median survival day (functional) | = 24.3 | Median survival day in P388 leukemia mice model when a dose of 100 mg/kg administered intravenously | ChEMBL. | 3339609 |
Median survival day (functional) | = 32.25 | Median survival day of B16 melanoma infected mice when a dose of 1.25 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median survival day (functional) | = 35.25 | Median survival day of B16 melanoma infected mice when a dose of 2.5 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median survival day (functional) | = 41.2499999999997 | Median survival day of B16 melanoma infected micee when a dose of 5 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
Median tumoral volume (functional) | = 0.97 cm*3 | Median survival day in C38 adenocarcinoma cell line when a dose of 75 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
Median tumoral volume (functional) | = 0.97 cm*3 | Median survival day in C38 adenocarcinoma cell line when a dose of 75 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
Median tumoral volume (functional) | = 1.38 cm*3 | Median survival day in C38 adenocarcinoma cell line when a dose of 50 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
Median tumoral volume (functional) | = 1.38 cm*3 | Median survival day in C38 adenocarcinoma cell line when a dose of 50 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
Median tumoral volume (functional) | = 3.24 cm*3 | Median tumoral volume of C38 adenocarcinoma model when a dose of 100 mg/kg administered intravenously on D1 to mice | ChEMBL. | 3339609 |
Median tumoral volume (functional) | = 3.24 cm*3 | Median tumoral volume of C38 adenocarcinoma model when a dose of 100 mg/kg administered intravenously on D1 to mice | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 1.25 mg/kg to B16 melanoma infected mice; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 2.5 mg/kg to B16 melanoma infected mice; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 10 mg/kg to B16 melanoma infected mice; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 5 mg/kg to P388 leukemia model; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 10 mg/kg to P388 leukemia model; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 40 mg/kg to P388 leukemia model; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day 30 when a dose of 50 mg/kg administered intravenously to P388 leukemia mice model; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day D30 when a dose of 20 mg/kg administered intravenously to L1210 leukemia mice model; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 0 | Survivors at day D30 when a dose of 40 mg/kg administered intravenously to L1210 leukemia mice model; 0/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 1 | Survivors at day 30 when a dose of 40 mg/kg to P388 leukemia model; 1/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 1 | Survivors at day 30 when a dose of 100 mg/kg administered intravenously to P388 leukemia mice model; 1/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 5 | Survivors at day 30 when a dose of 5 mg/kg to B16 melanoma infected mice; 5/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 10 | Survivors at day D38 when a dose of 100 mg/kg administered intravenously to C38 adenocarcinoma cell lines on D1 to mice; 10/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 10 | Survivors at day D32 when a dose of 50 mg/kg administered intravenously to C38 adenocarcinoma mice models; 10/10 | ChEMBL. | 3339609 |
Survivors (functional) | = 10 | Survivors at day D32 when a dose of 75 mg/kg administered intravenously to C38 adenocarcinoma mice models; 10/10 | ChEMBL. | 3339609 |
T/C (functional) | Toxic 0 % | Antitumour activity against P388 leukemia in mice at a dose of 20 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
T/C (functional) | = 79 % | Antitumour activity against B16 melanoma cells at a dose of 10 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 79 % | Antitumour activity against B16 melanoma cells at a dose of 10 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 132 % | Antitumour activity against L1210 leukemia mice model at a dose of 20 mg/kg administered intravenously | ChEMBL. | 3339609 |
T/C (functional) | = 132 % | Antitumour activity against L1210 leukemia mice model at a dose of 20 mg/kg administered intravenously | ChEMBL. | 3339609 |
T/C (functional) | = 133 % | Antitumour activity against B16 melanoma cells at a dose of 1.25 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 133 % | Antitumour activity against B16 melanoma cells at a dose of 1.25 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 139 % | Antitumour activity against P388 cells at a dose of 10 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
T/C (functional) | = 139 % | Antitumour activity against P388 cells at a dose of 10 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
T/C (functional) | = 145 % | Antitumour activity against B16 melanoma cells at a dose of 2.5 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 145 % | Antitumour activity against B16 melanoma cells at a dose of 2.5 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 149 % | Antitumour activity against P388 leukemia in mice at a dose of 2.5 mg/kg administered intraperitoneally for 5 days | ChEMBL. | 3339609 |
T/C (functional) | = 149 % | Antitumour activity against L1210 cells at a dose of 40 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
T/C (functional) | = 149 % | Antitumour activity against P388 leukemia in mice at a dose of 2.5 mg/kg administered intraperitoneally for 5 days | ChEMBL. | 3339609 |
T/C (functional) | = 149 % | Antitumour activity against L1210 cells at a dose of 40 mg/kg administered intravenously to mice | ChEMBL. | 3339609 |
T/C (functional) | = 156 % | Antitumour activity against P388 cells at a dose of 20 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
T/C (functional) | = 156 % | Antitumour activity against P388 cells at a dose of 20 mg/kg administered intraperitoneally | ChEMBL. | 3339609 |
T/C (functional) | = 166 % | Antitumour activity against P388 leukemia in mice at a dose of 5 mg/kg administered intraperitoneally for 5 days | ChEMBL. | 3339609 |
T/C (functional) | = 166 % | Antitumour activity against P388 leukemia in mice at a dose of 5 mg/kg administered intraperitoneally for 5 days | ChEMBL. | 3339609 |
T/C (functional) | = 170 % | Antitumour activity against B16 melanoma cells at a dose of 2.5 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 170 % | Antitumour activity against B16 melanoma cells at a dose of 2.5 mg/kg administered intraperitoneally to mice | ChEMBL. | 3339609 |
T/C (functional) | = 174 % | In vivo toxicity test on P388 cells at a dose of 50 mg/kg administered intravenously to P388 leukemia mice model | ChEMBL. | 3339609 |
T/C (functional) | = 174 % | In vivo toxicity test on P388 cells at a dose of 50 mg/kg administered intravenously to P388 leukemia mice model | ChEMBL. | 3339609 |
T/C (functional) | = 182 % | Antitumour activity against P388 cells at a dose of 40 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
T/C (functional) | = 182 % | Antitumour activity against P388 cells at a dose of 40 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
T/C (functional) | = 202 % | Antitumour activity against P388 cells at a dose of 80 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
T/C (functional) | = 202 % | Antitumour activity against P388 cells at a dose of 80 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
T/C (functional) | = 205 % | Antitumour activity against P388 leukemia in mice at a dose of 10 mg/kg administered intraperitoneally for 5 days | ChEMBL. | 3339609 |
T/C (functional) | = 205 % | Antitumour activity against P388 leukemia in mice at a dose of 10 mg/kg administered intraperitoneally for 5 days | ChEMBL. | 3339609 |
T/C (functional) | = 223 % | In vivo toxicity test on P388 cells at a dose of 100 mg/kg administered intravenously to P388 leukemia mice model | ChEMBL. | 3339609 |
T/C (functional) | = 223 % | In vivo toxicity test on P388 cells at a dose of 100 mg/kg administered intravenously to P388 leukemia mice model | ChEMBL. | 3339609 |
Tumor volume (functional) | = 13 % | Antitumour activity against C38 adenocarcinoma cells at a dose of 75 mg/kg administered intravenously to mice ; tumor volume at D32 (T/C) | ChEMBL. | 3339609 |
Tumor volume (functional) | = 13 % | Antitumour activity against C38 adenocarcinoma cells at a dose of 75 mg/kg administered intravenously to mice ; tumor volume at D32 (T/C) | ChEMBL. | 3339609 |
Tumor volume (functional) | = 18 % | Antitumour activity against C38 adenocarcinoma cells at a dose of 50 mg/kg administered intravenously to mice ; tumor volume at D32 (T/C) | ChEMBL. | 3339609 |
Tumor volume (functional) | = 18 % | Antitumour activity against C38 adenocarcinoma cells at a dose of 50 mg/kg administered intravenously to mice ; tumor volume at D32 (T/C) | ChEMBL. | 3339609 |
Tumor volume (functional) | = 36 % | Antitumour activity against C38 adenocarcinoma cells at a dose of 100 mg/kg administered intravenously on D1 to mice ; tumor volume at D32 (T/C) | ChEMBL. | 3339609 |
Tumor volume (functional) | = 36 % | Antitumour activity against C38 adenocarcinoma cells at a dose of 100 mg/kg administered intravenously on D1 to mice ; tumor volume at D32 (T/C) | ChEMBL. | 3339609 |
Weight change (functional) | = -5.2 g | Weight change in g when a dose of 100 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = -5.2 g | Weight change in g when a dose of 100 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = -2.5 g | Weight change in g when a dose of 1.25 mg/kg administered intraperitoneally to B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = -2.5 g | Weight change in g when a dose of 1.25 mg/kg administered intraperitoneally to B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = -1.6 g | Weight change in g when a dose of 100 mg/kg intravenous administration to P388 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -1.6 g | Weight change in g when a dose of 100 mg/kg intravenous administration to P388 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -1.2 g | Weight change in g when a dose of 80 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = -1.2 g | Weight change in g when a dose of 80 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = -1 g | Weight change in g when a dose of 10 mg/kg administered intraperitoneally B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = -1 g | Weight change in g when a dose of 10 mg/kg administered intraperitoneally B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = -0.7 g | Weight change in g when a dose of 50 mg/kg intravenous administration to P388 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.7 g | Weight change in g when a dose of 50 mg/kg intravenous administration to P388 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.6 g | Weight change in g when a dose of 20 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.6 g | Weight change in g when a dose of 20 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.4 g | Weight change in g when a dose of 20 mg/kg intravenous administration to L1210 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.4 g | Weight change in g when a dose of 20 mg/kg intravenous administration to L1210 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.2 g | Weight change in g when a dose of 40 mg/kg intravenous administration to L1210 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = -0.2 g | Weight change in g when a dose of 40 mg/kg intravenous administration to L1210 leukemia mice model | ChEMBL. | 3339609 |
Weight change (functional) | = 0.1 g | Weight change in g when a dose of 10 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = 0.1 g | Weight change in g when a dose of 10 mg/kg administered intraperitoneally to P388 leukemia model | ChEMBL. | 3339609 |
Weight change (functional) | = 0.2 g | Weight change in g when a dose of 5 mg/kg administered intraperitoneally B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = 0.2 g | Weight change in g when a dose of 5 mg/kg administered intraperitoneally B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = 0.6 g | Weight change in g when a dose of 2.5 mg/kg administered intraperitoneally B16 melanoma infected mice | ChEMBL. | 3339609 |
Weight change (functional) | = 0.6 g | Weight change in g when a dose of 2.5 mg/kg administered intraperitoneally B16 melanoma infected mice | ChEMBL. | 3339609 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.